ANI Pharmaceuticals Inc (NASDAQ:ANIP) has been given a consensus rating of “Buy” by the seven analysts that are presently covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $71.00.

ANIP has been the subject of a number of recent research reports. ValuEngine upgraded shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, November 4th. TheStreet upgraded shares of ANI Pharmaceuticals from a “c+” rating to a “b” rating in a report on Thursday, November 16th. Zacks Investment Research upgraded shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating and set a $71.00 price target for the company in a report on Tuesday, November 7th. Canaccord Genuity set a $75.00 price target on shares of ANI Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, December 9th. Finally, BidaskClub downgraded shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, December 21st.

A number of institutional investors have recently added to or reduced their stakes in ANIP. BNP Paribas Arbitrage SA grew its holdings in ANI Pharmaceuticals by 44.6% in the second quarter. BNP Paribas Arbitrage SA now owns 2,152 shares of the specialty pharmaceutical company’s stock valued at $101,000 after purchasing an additional 664 shares during the period. Bank of Montreal Can grew its holdings in ANI Pharmaceuticals by 681.8% in the fourth quarter. Bank of Montreal Can now owns 2,408 shares of the specialty pharmaceutical company’s stock valued at $156,000 after purchasing an additional 2,100 shares during the period. SG Americas Securities LLC purchased a new stake in ANI Pharmaceuticals in the third quarter valued at approximately $197,000. Stevens Capital Management LP purchased a new stake in ANI Pharmaceuticals in the second quarter valued at approximately $207,000. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in ANI Pharmaceuticals in the second quarter valued at approximately $210,000. Hedge funds and other institutional investors own 55.05% of the company’s stock.

Shares of ANI Pharmaceuticals (NASDAQ:ANIP) opened at $69.74 on Friday. The company has a market cap of $811.99, a PE ratio of 110.70 and a beta of 2.90. ANI Pharmaceuticals has a twelve month low of $42.23 and a twelve month high of $74.70. The company has a current ratio of 3.45, a quick ratio of 2.39 and a debt-to-equity ratio of 0.83.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported $1.11 EPS for the quarter, topping analysts’ consensus estimates of $0.99 by $0.12. The business had revenue of $48.16 million during the quarter, compared to the consensus estimate of $48.12 million. ANI Pharmaceuticals had a net margin of 4.45% and a return on equity of 22.40%. The company’s quarterly revenue was up 25.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.09 earnings per share. research analysts predict that ANI Pharmaceuticals will post 3.59 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This piece of content was first published by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/ani-pharmaceuticals-inc-anip-receives-consensus-recommendation-of-buy-from-analysts-2/1812991.html.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.